2013 American Transplant Congress
Metabolomic Distinctions between Renal Allograft Recipients on Monotherapy Sirolimus or Tacrolimus Maintenance Therapy
Background. Sirolimus and Tacrolimus have distinct mechanisms of action with distinct side effect profiles. In order to gain mechanistic insights into the differing effects of…2013 American Transplant Congress
Antiviral Prophylaxis for HBsAg-Positive Renal Transplant Recipients Treated with Rituximab®
The risk of Hepatitis B virus (HBV) reactivation under immunosuppressant has been well known. Especially, rituximab® is identified as strong risk factors of HBV reactivation…2013 American Transplant Congress
Delayed Kidney Graft Function in SPK Recipients Is Associated with Poor Long-Term Outcomes
The association of delayed kidney graft function (DGF) with long-term clinical outcomes in simultaneous pancreas kidney (SPK) transplant recipients is largely unknown. To address this…2013 American Transplant Congress
Treatment Option in Diabetic End Stage Renal Disease Patients with Potential Living Kidney Donor: PAK vs. SPLK
In diabetic patients with end stage renal disease who has a potential living kidney donor, pancreas after living kidney transplantation (PAK) or simultaneous cadaveric pancreas…2013 American Transplant Congress
Disease Severity Index Based on Dual Cholate Clearances and Shunt Identifies Primary Sclerosing Cholangitis Waiting List Patients at Risk for Clinical Complications, A
Gastroenterology and Hepatology, University of Colorado, Aurora, CO
A. Purpose: MELD may not adequately assess the risks for clinical complications in listed Primary Sclerosing Cholangitis (PSC) patients compared to a disease severity index…2013 American Transplant Congress
Development of De Novo Anti-HLA Antibodies after Treatment with/without Rituximab, a B Cell−Depleting Treatment
Urology, 8-1 Kawada-Cho, Shinjuku-ku, Tokyo, Japan
Background: Organ shortages have forced a widening of the indications for kidney donors. In Japan, ABO-incompatible kidney transplantation (ABOi) is a popular alternative to deceased…2013 American Transplant Congress
Monoclonal Antibody Which Possibly May Replace the Therapeutic Intravenous Immunoglobulin, A
HLA Antibodies, Terasaki Foundation Laboratory, Los Angeles, CA
The value of intravenous immunoglobulin (IVIg) in lowering HLA antibodies (Abs) has recently come into question. High variability in different therapeutic preparations may account for…2013 American Transplant Congress
Prevalence of Human Papillomavirus (HPV) Infection in Female Kidney Transplant Recipients
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, DF, Mexico
Introduction: Kidney transplant recipients are at higher risk for viral infection-related cancers. Even though HPV infection is strongly associated with several genital cancers, data on…2013 American Transplant Congress
Tacrolimus Concentration Variability Is Associated with Delayed Graft Function and Diminished Renal Function in Kidney Transplant Recipients
Pharmacy, MUSC, Charleston, SC; Surgery, MUSC, Charleston, SC
Background: Tacrolimus (FK) is the drug of choice for preventing acute allograft rejection in kidney transplantation. However, therapeutic drug monitoring is necessary due to FK’s…2013 American Transplant Congress
Tacrolimus Metabolism Rate Influences the Kidney Function after Liver Transplantation, The
Introduction: The calcineurin inhibitor (CNI) tacrolimus is a very effective immunosuppressive drug after liver transplantation (LTx) but is often associated with an impaired renal function.…
- « Previous Page
- 1
- …
- 155
- 156
- 157
- 158
- 159
- …
- 178
- Next Page »